Read This First!

Hello, AlzClub and AlzheimerCode are not-for-profit web sites for non-censored ideas, news, research, technology and clinics on Alzheimer's disease and related disorders. Both are run personally by me, Alexei Koudinov, MD, PhD, DrSci, well known for his Alzheimer's and basic science research, and for battling against the corruption of Alzheimer's field, to protect public interest. Few examples are under must read links above, most notable of which are correspondence with the Wall Street Journal that yielded three WSJ articles on Alzheimers, Security and Exchange Commission (SEC) and Written Evidence to UK Parliamentary committee. My contrubution to Alzheimer's research is summarized in cholesterol failure hypothesis of Alzheimer's and in the series of publications here. - With love, Alexei Koudinov

Alzforum Professional News & Views


google search

November 10, 2010

Why there is no cure for Alzheimer's disease?

Based on Society for Neuroscience Ethics in Neurosciences Abstract 2010:

Koudinov, Alexei. Why ethical and policy issues topic of the Society for Neuroscience annual meetings is overdue? Program No. 28.4. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Available online at abstractsonline.com

Neuroscience is a human activity that has lots of features only insiders can talk about with confidence. While general public may consider science is a privilege of those with high IQ, for many behind a university campus wall (or commercial lab secrecy) it is a matter of surviving, battling for funds, lab space, equipment access, and tenure. It is so great to have a confidence you are set up until a pension age. It was long time ago that you had a scientific quest excitement and late night lab hours of experimentation. Surely, you built your research on the data by others, heavily quoted a field leader, prominent Professor of the national premier research center you dreamed about as a postdoc or a faculty member. You could not know that this Professor had industry appointments and that he sold his million dollar stock shortly before the clinical trial on devastating human brain disorder failed (1). Well, you thought this failure could be a failure of the major theory of the disease. But who cares? A number of years ago you read an article in the Wall Street Journal (2) that called this theory a dogma retarding the development of the true disease cure. Would it be practical to you to combat the field corruption? Can one be a warrior? The natural answer for you as an ordinary human being is not: NOT at a postdoc time, because otherwise who of the field leadership would say “yes” to your tenure promotion and approval? NOT now (when you are a senior professor) because you have so many ties. Our World is in fact small, so, you take your tenure/grants as a fragile substance and prefer to be not so loud. You recall five years ago or so British Parliament published written evidence, a fact based encyclopedia of the corruption in your research field (3). But its’ impact is remote, as no one wants to take ethical issues seriously or talk on them openly. Several no-response open statements by a caring scientist to US Office of Research Integrity ORI, SEC and British Office of Fair Trading are all examples that in neurosciences patients are forgotten, commercial interests or one’s Ego are ruling (1). Well, you hope the SFN takes a leadership by introducing new annual meeting topic of Ethical issues in Neurosciences, and that as of now evidence based facts of wrongdoing will be not that easy to hide. Openness means change for good. Good in science means public non-private interest in scientific findings.

References:

1. http://business.timesonline.co.uk/tol/business/article1017839.ece
2. http://neurobiologyoflipids.org/editors/alexeikoudinov/pdfdocs/submittedletters/koudinov2wsj23april04.html
3. http://www.publications.parliament.uk/pa/cm200304/cmselect/cmsctech/399/399we125.htm
4. http://twitter.com/alzforum

2 comments:

Anonymous said...

Dear Blogger,

Hope this email finds you well. This is Sharon from CNN's Asia-Pacific headquarters based in Hong Kong.

We are reaching out to you because we understand that you are one of the most influential and authoritative voices when it comes to Alzheimer's or health-related issues in your country, and you may be interested in CNN's WORLD UNTOLD STORIES which features Early-Onset-Alzheimer's Disease in February, and Kenya's mentally-handicapped community in March.

It is our hopes that you would run a preview of these shows in your blog to increase social awareness of these pressing health and social issues which are often overlooked or underrated.

In February CNN's award-winning monthly documentary series WORLD'S UNTOLD STORIES brings you face to face with the cruel realities of Alzheimer's this weekend. Titled "FILLING THE BLANK", it follows stories of Early-Onset Alzheimer's Disease families around the world on their struggle to survive and investigates the possibility of finding a cure. The show airs Feb 19 at 22.00 HKT and Feb 20 at 18.00 HKT.

Also a heads up that WORLD'S UNTOLD STORIES will be featuring another health issue in its March show - all the way to Kenya. This episode explores the "LOCKED UP AND FORGOTTEN" world of the mentally-handicapped in the country, and the lack of support that the government and international community is giving to this torn and abused group and their families. This is a very powerful documentary which exposes the harsh and largely unknown conditions of the lives of these people in Kenya with unprecedentedly raw and in-depth footage.

For detailed show synopsis, images, and video tease, please find below:

"FILLING THE BLANK"
http://www.cnnasiapacific.com/edm/mkt_edm/pr/110210_wus_fillingtheblank/fillingtheblank_110210.html

"LOCKED UP AND FORGOTTEN"
http://www.cnnasiapacific.com/edm/mkt_edm/PR/110216_wus_lockedupandforgotten/lockedupandforgotten_110216.html

For more details of WORLD'S UNTOLD STORIES, visit the program's website at www.cnn.com/wus.

Please feel free to reach out to me should you be interested in the shows or if you have any queries. My contact details are listed below.

Many thanks and looking forward to hearing from you.

Best regards,
Sharon

Sharon LS Chan
Public Relations Coordinator

CNN Asia Pacific
Tel: (852) 3128 3522
Email: sharon.chan@turner.com
Twitter: cnnasiapr

Julian Lieb,M.D said...

THE REMARKABLE HUMAN AND ECONOMIC VALUE OF ANTIDEPRESSANTS IN PREVENTING AND ALLEVIATING ALZHEIMER’S DISEASE
-----------------------------------Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram.
Lavretsky H, Siddarth P, Irwin MR. Am J Geriatr Psychiatry. 2010 Feb; 18(2):154-62.PMID: 20104071 [PubMed - indexed for MEDLINE
Anti-inflammatory effects of antidepressants: possibilities for preventives against Alzheimer's disease. Hashioka S, McGeer PL, Monji A, Kanba S.
Cent Nerv Syst Agents Med Chem. 2009 Mar; 9(1):12-9. Review.PMID: 20021334 [PubMed - indexed for MEDLINE]
Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease.
Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, Pérault-Pochat MC, Lafay-Chebassier C. J Pharmacol Exp Ther. 2010 Feb; 332(2):505-14. Epub 2009 Nov 4.
Involuntary emotional expression disorder in Alzheimer's disease - psychopharmacotherapy aspects. Mimica N, Drmić S, Presecki P. Psychiatr Danub. 2009 Sep; 21(3):425-8.
Untangling the roles of antidepressants and mood stabilizers in the treatment of Alzheimer's disease. Introduction. Reiman EM. J Clin Psychiatry. 2009 Jun;70(6):913-4. No abstract available.
Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. Siddique H, Hynan LS, Weiner MF. J Clin Psychiatry. 2009 Jun; 70(6):915-8. Epub 2009 May 5.
Antidepressants and dementia. Kessing LV, Søndergård L, Forman JL, Andersen PK.
J Affect Disord. 2009 Sep; 117(1-2):24-9. Epub 2009 Jan 12.
Int Rev Psychiatry. 2008 Aug; 20(4):382-8.
Depression in Alzheimer's disease: phenomenology, clinical correlates and treatment.
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
Tosto G, Talarico G, Lenzi GL, Bruno G. Neurol Sci. 2008 Sep; 29(4):269-70. Epub 2008 Sep 20
Dement Geriatr Cogn Disord. 2008; 25(4):372-9. Epub 2008 Mar 20. Is antidepressant treatment associated with reduced cognitive decline in Alzheimer's disease? Mossello E, Boncinelli M, Caleri V, Cavallini MC, Palermo E, Di Bari M, Tilli S, Sarcone E, Simoni D, Biagini CA, Masotti G, Marchionni N. Department of Critical Care Medicine and Surgery, Unit of Gerontology and Geriatric Medicine, University of Florence and Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. enrico.mossello@unifi.it J Biol Chem. 2007 Nov 9; 282(45):32676-88. Epub 2007 Sep 2.
Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. Hoshino T, Nakaya T, Homan T, Tanaka K, Sugimoto Y, Araki W, Narita M, Narumiya S, Suzuki T, Mizushima T.Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862-0973, Japan. J Biol chem. 2007 Nov 9; 282(45):32676-88. Epub 2007 Sep 2.
,
BIOCHEMICAL AND PHARMACOLOGICAL INTERPRETATIONS

As depression predisposes to Alzheimer’s disease,, it is reasonable to suspect that antidepressants are capable of preventing, alleviating and arresting the disorder. Excessive synthesis of prostaglandin E2 generates amyloid. Such non-steroidal anti-inflammatory drugs as aspirin and ibuprofen, as well as antidepressants, inhibit prostaglandin E2. Two major epidemical studies have shown that ibuprofen (Motrin) that specifically inhibits prostaglandins, can significantly delay the onset of Parkinson’s disease, a neurodegenerative disorder closely related to Alzheimer’s.

Latest PubMed.gov research articles on Alzheimer’s